Plain-English translation of NCT06254261 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Obesity research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a research study testing a medication called to see if it can help people with obesity. The study will check whether the medication is safe, how well people tolerate it, and whether it actually helps with weight loss. About 270 people will participate, with some receiving the medication and others receiving a placebo (a dummy injection) to compare results.
Obesity is a serious health condition that increases the risk of many other diseases like heart problems, diabetes, and sleep apnea. Current treatment options are limited, so researchers are testing this new medication to see if it offers people another safe and effective way to manage their weight.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic every two weeks for 24 weeks (about 6 months). At each visit, you'll receive an injection under the skin—either the new medication or a placebo. The research team will monitor your weight, check your blood pressure and blood work, and ask about any side effects you experience. You'll also need to keep track of how you're feeling between visits.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Guangdong Raynovent Biotech Co., Ltd
Enrollment target
~270 participants
Started
February 2024
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
JI, professor
Guangdong Raynovent Biotech Co., Ltd
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.